Provided herein are compositions, kits, and methods for measuring circulating cytokines and chemokines in a subject that has or is suspected of having Celiac disease.

Methods of identifying an individual as being a slow gingivitis responder or a high gingivitis responder are disclosed. Some methods are based on IL-1 levels in the individual's GCF at the site of inflammation. Some methods are based on MIF and/or CCL-1 levels in the individual's GCF in healthy tissue distant from the site of inflammation. Some disclosed methods are based on temporal differences in IL-8, IL-6 and/or TNF levels in the individual's GCF in healthy tissue distant from the site of inflammation during the development of plaque induced inflammation. Methods of treating an individual who has gingivitis and methods of preventing gingivitis are also provided. The treatment and prevention methods comprise determining if individual is a slow gingivitis responder or a high gingivitis responder and applying oral care compositions to the individual's oral cavity.

The present disclosure provides methods and compositions that find use in facilitating a diagnosis of inflammatory liver disease in a subject. The methods and compositions generally involve detection of eotaxin-3 (E3) levels, either alone or with levels of eotaxin-1 (E1), and optionally, with levels of CCL22 and, further optionally, with levels of IL15. These levels can be used to facilitate a diagnosis of a liver disease of at least one of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), and/or to facilitate a differential diagnosis between AIH, PBC, and PSC. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject.

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.

Biomarkers, methods, devices, reagents, systems, and kits used to assess the quality of a sample collected from a subject are provided. Such biomarkers, methods, devices, reagents, systems, and kits may be useful in evaluating acceptability of sample handling and/or consistency of sample handling across a plurality of samples.

Biomarker-based treatment, monitoring, and diagnostic methods for IL-17 dependent conditions, including hidradenitis suppurativa, are disclosed. The biomarkers may be selected from IL6, PLA2G2A, IL19, P13, CST7, IL17A, IL17F, GH1, MZB1, IL1B, IFNG, TNC, CXCL9, SLAMF7, VEGFA, IL17C, SLAMF1, SDC1, OSM, LBP, REG3A, CD79B, COL4A1, CLEC4D, VWF, IL5RA, CSF3, TGFA, IL2RA, ITIH3, FCAR, CCL23, NRCAM, RETN, SERPINA11, CLEC4G, CSF1, HGF, CRELD2, EFEMP1, LTBR, NME3, CKAP4, CD276, SPON2, GGH, TIMP1, LY9, MCFD2, TCN2, QPCT, HYOU1, TNSFSF13B, CCL2, CCL3, CCL4, CCL5, CCL7, CCL20, CXCL1, CXCL8, PDFGA, CXCR2, CCR6, CXCL13, PCDH1, BOC, MEPE, ADAM 23, THOP1, IL1RL2, RCOR1, EDAR, and combinations thereof. Kits for measuring the biomarkers, diagnosing and treating IL-17-dependent conditions, and identifying super-responders are also disclosed.

Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.

Disclosed are methods of treating sepsis in an individual in need thereof via administration of a therapeutically effective amount of a humanin protein, or an analog thereof, to the individual. In one aspect, the methods may comprise administration of the humanin analog colivelin for reducing lung, liver and kidney injury and systemic inflammation after an infection.

The present disclosure provides a whole blood, protein-based diagnostic test for presence and evaluation of aneurysm status. Further, the present disclosure relates to methods of treating aneurysms.

Described herein is method of treating, ameliorating and/or preventing a wound in a subject in need thereof. The method includes: collecting a first sample from the wound at a first timepoint and determining a first CCL1 (chemokine ligand 1) level in the first sample; administering to the subject a first treatment that promotes wound healing; collecting a second sample from the wound at a second timepoint after the first timepoint and determining a second CCL1 level in the second sample; and (a) if the second CCL1 level is higher than the first CCL1 level times a predetermined value, continuing the administration of the first treatment or discontinuing the first treatment, (b) if the second CCL1 level is equal to or lower than the CCL1 level times the predetermined value, administering to the subject a second treatment that promotes wound healing.